Cholecalciferol (Vitamin D3) Encyclopedia — Scientific Background

What Is Cholecalciferol?

Cholecalciferol (CAS 67-97-0), also known as vitamin D3 or colecalciferol, is a fat-soluble secosteroid with the molecular formula C₂₇H₄₄O and a molecular weight of 384.64 g/mol. It is chemically designated as (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol. Cholecalciferol occurs as white to almost white crystals or crystalline powder that is practically insoluble in water, freely soluble in ethanol (96%), and soluble in fatty oils.

The Lanolin Source

Lanolin is a waxy substance naturally secreted by wool-bearing mammals that contains 7-dehydrocholesterol (7-DHC), a zoosterol that functions as a provitamin D3. 7-DHC is photochemically converted to vitamin D3 in the skin upon exposure to UVB radiation and is the same compound found in human skin that enables humans to manufacture vitamin D3. In the commercial production of vitamin D3, lanolin is subjected to a series of purification steps to form 7-dehydrocholesterol before being converted to cholecalciferol via UV irradiation. Lanolin is the most commonly used raw material for the production of vitamin D in dietary supplements.

Crystalline vitamin D3 meets the requirements of USP, Ph.Eur., FCC, and IP, with 1 gram of cholecalciferol equaling 40,000,000 IU of vitamin D3.

Physiological Functions of Vitamin D3

Vitamin D3 is critical for numerous physiological functions:

• Calcium and Phosphorus Homeostasis — Vitamin D3 promotes intestinal calcium absorption and renal calcium reabsorption, maintaining normal serum calcium and phosphorus levels essential for bone mineralization and neuromuscular function.

• Bone Health — Vitamin D3 supports bone mineralization and is essential for the prevention and treatment of rickets in children and osteomalacia in adults.

• Immune Function — Vitamin D3 modulates both innate and adaptive immune responses, supporting the body‘s natural defense mechanisms.

• Neuromuscular Function — Vitamin D3 contributes to normal muscle function and neuromuscular signaling.

• Cell Growth and Differentiation — Vitamin D3 regulates cell growth, differentiation, and apoptosis, supporting normal cellular function.

Mechanisms of Action

Vitamin D Receptor (VDR) Signaling

Vitamin D3 is metabolized to 25-hydroxyvitamin D3 in the liver and then to the biologically active 1,25-dihydroxyvitamin D3 in the kidneys. The active metabolite binds to the vitamin D receptor (VDR), a nuclear receptor that regulates the transcription of target genes involved in calcium and phosphorus homeostasis, bone metabolism, immune function, and cell growth.

Calcium Absorption and Bone Mineralization

Vitamin D3 enhances intestinal calcium absorption by increasing the expression of calcium transport proteins, including TRPV6 and calbindin-D9k, in the intestinal epithelium. It also promotes renal calcium reabsorption and regulates parathyroid hormone (PTH) secretion, maintaining normal calcium homeostasis essential for bone mineralization.

Immune Modulation

Vitamin D3 modulates immune function by regulating the activity of immune cells, including T lymphocytes, macrophages, and dendritic cells. It enhances the antimicrobial activity of monocytes and macrophages and modulates cytokine production, supporting both innate and adaptive immune responses.

The Bioavailability Challenge

Despite its essential physiological functions, conventional oral cholecalciferol presents significant bioavailability challenges. As a highly lipophilic molecule, D3 is commonly dosed in oils or solid dosage forms that can be poorly palatable, slow to absorb, or unstable in aqueous settings. Additionally, cholecalciferol absorption is dependent on bile salt-mediated micelle formation and is influenced by dietary fat intake, leading to variability in bioavailability. Vitamin D deficiency is increasingly prevalent and linked to impaired health and disease, and while vitamin D3 supplementation is effective, variability in absorption can influence bioavailability and clinical responses.

These limitations have driven the development of advanced delivery systems, including liposomal encapsulation. A clinical experiment demonstrated for the first time that absorption of vitamin D3 in liposomes depends on vitamin D status, with Liposomal vitamin D3 absorbed faster by persons with distinct deficiency.

Liposomal Cholecalciferol

Liposomal encapsulation of cholecalciferol provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the cholecalciferol molecule, forming a protective shell that enhances stability, bioavailability, and cellular uptake. This delivery system:

• Achieves 1.9-fold higher AUC compared to non-liposomal formulations in a randomized double-blind crossover clinical study

• Achieves higher peak concentration (8.4 vs 6.0 ng/mL) and sustained elevation above baseline at 48 hours

• Demonstrates encapsulation efficiency exceeding 97% with zeta potential values lower than −45 mV

• Improves storage stability and stability in aqueous and gastrointestinal environments

• Demonstrates rapid absorption in deficiency states, especially pronounced for people with severe vitamin D3 deficiency

Clinical Evidence

Enhanced Acute Absorption — Randomized Controlled Trial

A randomized, double-blind, crossover absorption study enrolled 12 healthy adults (mean age 34.3 ± 9.7 years; BMI 24.8 ± 2.7 kg/m²) to compare the absorption of a liposomal vitamin D3 formulation with a conventional non-liposomal formulation. Healthy adult participants received a single oral dose of both formulations in random order separated by a 2-week washout period. Blood samples were collected over 48 hours post-dose, and plasma cholecalciferol concentrations were quantified. The liposomal formulation showed greater systemic absorption compared with the comparator formulation, with a 1.9-fold higher AUC (199 vs 106 ng·h/mL). Peak concentration was also higher for the liposomal formulation (8.4 vs 6.0 ng/mL). Circulating cholecalciferol concentrations remained elevated above baseline at 48 hours in the liposomal formulation but returned to baseline in the comparator formulation.

Rapid Absorption in Deficiency States

A clinical experiment compared liposomal vitamin D3 with an oily formulation. The results showed that liposomal vitamin D3 causes a rapid increase in the plasma concentration of calcidiol, while no such effect was observed when the oily formulation was used. The effect was especially pronounced for people with severe vitamin D3 deficiency. This was the first demonstration that absorption of vitamin D3 in liposomes depends on its status in the organism, with liposomal vitamin D3 absorbed faster by persons with distinct deficiency.

Pharmacokinetic Study — 24-Hour Period

A pharmacokinetic study exploring liposomal D3 uptake within blood plasma over a 24-hour period demonstrated that the AUC revealed an almost 3 times increase in absorption of the liposomal formulation compared to a nano-emulsion formulated oral spray. The study concluded that liposomal technology can be used as a successful delivery method of vitamin D3 and evidently improves administration over a 24-hour period.

Safety and Regulatory

Vitamin D3 has a well-established safety profile when used appropriately. The Tolerable Upper Intake Level (UL) for vitamin D is 4,000 IU/day for adults, although higher doses may be used under medical supervision. Excessive intake of vitamin D can cause hypercalcemia, which may result in nausea, vomiting, weakness, and renal complications.

Regulatory Status:

• United States — Cholecalciferol is regulated as a dietary supplement ingredient and food additive. Crystalline vitamin D3 is affirmed as Generally Recognized as Safe (GRAS) by the FDA under 21 CFR § 182.5950 for use as a direct human food ingredient. It is listed in the FDA Substances Added to Food database with CAS Registry No. 67-97-0. Food additive and GRAS regulations: 21 CFR 172.380.

• European Union — Cholecalciferol is monographed in the European Pharmacopoeia (Ph. Eur. monograph 0072) and is authorized as a vitamin and mineral substance which may be used in the manufacture of food supplements. EU maximums vary by member state.

• Global Standards — Cholecalciferol is monographed in the USP, European Pharmacopoeia, British Pharmacopoeia, and Japanese Pharmacopoeia. The product complies with USP/EP/BP specifications including specific optical rotation (+105° to +112°), specific absorbance at 265 nm, and melting point (83–86°C). It is available with Halal and Kosher certifications.

Precautions: Cholecalciferol is generally well tolerated at recommended doses. Excessive intake of vitamin D can cause hypercalcemia, which may result in nausea, vomiting, weakness, and renal complications. Individuals with hypercalcemia, hyperphosphatemia, or severe renal impairment should consult a healthcare professional before use. Pregnant or lactating women and children should consult a healthcare professional before use. Cholecalciferol may interact with certain medications, including thiazide diuretics, cardiac glycosides, and corticosteroids.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, British Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

109$/KG

89$/KG